Ibio, Inc. · NASDAQ:IBIO
Ibio — IPO Roadshow (June 2018)
24 slides from Ibio's IPO roadshow presentation, Jun 13, 2018
Slide 1: Creating and Enabling Next-Generation Biologics
Creating and Enabling Next - Generation Biologics June 2018 Filed Pursuant to Rule 433 Registration No. 333 - 224620 Issuer Free Writing Prospectus dated June 13, 2018 Relating to Preliminary Prospectus dated June 11, 2018
Slide 2: Forward-Looking Statements
Forward - Looking Statements Non - Confidential 1 STATEMENTS INCLUDED IN THIS PRESENTATION RELATED TO IBIO, INC . MAY CONSTITUTE FORWARD - LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 . SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH
Slide 3: Issuer Free Writing Prospectus Issued Pursuant to SEC Rule 433
2 2 2 • Issuer Free Writing Prospectus Issued Pursuant to SEC Rule 433 • This free writing prospectus relates to the proposed public offering of Series A Preferred Stock and Common Stock of iBio , Inc. (the “Company”) all of which are being registered on a Registration Statement on Form S - 1 (No. 3
Slide 4: Offering Summary
3 Offering Summary Non - Confidential 3 Offering Summary Issuer iBio, Inc. Exchange / Ticker NYSE American / IBIO Offering Size Approximately $16,000,000 (100% Secondary) Over Allotment 15% (100% Secondary) Use of Proceeds Working Capital Lead Book - Runner A.G.P. / Alliance Global Partners
Slide 5: Non-Financial Corporate Assets
4 Non - Confidential 4 Non - Financial Corporate Assets Plant - Based Technology Platform • Proprietary gene expression technology to rapidly produce high levels of target proteins; applicable to most protein - based biologics • Extensive monoclonal antibody experience • Financial interest in produc
Slide 6: Plant-Based Technology Platform
Plant - Based Technology Platform Non - Confidential 5
Slide 7: iBio's Plant-Based Technology Platform
6 iBio’s Plant - Based Technology Platform Non - Confidential 6 A vector is created with a cDNA sequence encoding the target protein and plant viral gene components that increase expression over competitive technologies The vector is implanted in agrobacteria Plants are infiltrated with the agro - b
Slide 8: iBio Plant-Based Technologies: Ongoing Innovation and Protection
7 7 iBio Plant - Based Technologies: Ongoing Innovation and Protection Non - Confidential 7 Dynamic Continuing Invention with Appropriate Global Protection • 80+ issued patents in various countries, 26 U.S. • 39+ active patent applications, 6 U.S • More applications progressing to filing • Invention
Slide 9: Confirmed Successes of iBio Biopharmaceutical Technologies
Confirmed Successes of iBio Biopharmaceutical Technologies Validation in Clinical and Preclinical Product Tests • Rapid, Large - Scale Manufacturing Response to Pandemic Outbreak or Bioterror Attack – DARPA • Monoclonal Antibody Proteins – Confidential Clients & iBio • Growth Factors – Confidential
Slide 10: CDMO Business
9 CDMO Business Non - Confidential 9
Slide 11: Creation of iBio CDMO in Partnership with Eastern Capital
Creation of iBio CDMO in Partnership with Dart’s Eastern Capital History − DARPA’s Blue Angel Program funded most of $68 million Texas biomanufacturing facility (built in 2011 and owned then by Caliber Biotherapeutics) to address national security threats from pandemic disease and bioterrorism − Jan
Slide 12: Why Customers Are Choosing iBio CDMO
Why Customers Are Choosing iBio CDMO Reduced time at each stage of development speeds product launch • Early product candidate screening can be conducted faster and more broadly than with mammalian cell systems • Eliminates the need for stable cell line selection • Expanding hydroponic plant product
Slide 13: Why Customers Are Choosing iBio CDMO (Cont'd)
Why Customers Are Choosing iBio CDMO (Cont’d) Non - Confidential 12 • Time Compression Provides Direct Value to the Client • Lower Total Costs of Service Provide iBio with Higher Margins Without Increasing the Price to the Client
Slide 14: iBio CDMO Revenue Sources
13 13 iBio CDMO Revenue Sources Early stage lead screening, selection, and optimization Product - specific process development, especially useful for antibody derivatives prior to preclinical toxicology Production for preclinical testing, both R&D and IND - enabling Manufacturing for phase 1 clinica
Slide 15: iBio CDMO Capacity & Expansion Opportunities
14 14 iBio CDMO Capacity & Expansion Opportunities • 124,000 square foot facility with current operating capacity up to 2.2 million plants / 150 kilograms of therapeutic protein API per year − Multi - product capability − If all large - scale capacity is used for antibody API, annual commercial manu
Slide 16: Equity in Proprietary Products
15 Equity in Proprietary Products Non - Confidential 15
Slide 17: iBio Product Strategy: Lead Candidate, IBIO-CFB03
iBio Product Strategy: Lead Candidate, IBIO - CFB03 • In development for treatment of systemic sclerosis, idiopathic pulmonary fibrosis (IPF), and localized scleroderma • Orphan Drug Designation in the U.S. • Preclinical data indicate potential use for both inhibition & reversal of fibrosis − Human
Slide 18: iBio Fibrosis Product Value Potential
17 iBio Fibrosis Product Value Potential • Roche’s Esbriet®, developed by InterMune for IPF, neither reverses fibrotic disease nor increases overall survival Kaplan - Meier Estimates of All - Cause Mortality at Vital Status – End of Study: Studies 1, 2 and 3 • The drug was launched in 2014 at a whol
Slide 19: Key Value Drivers in 2018 and Beyond
Key Value Drivers in 2018 and Beyond 18 Facility Design Services Non - Confidential Global Opportunities Partnered & Proprietary Products CDMO Cash Flow Other
Slide 20: iBio Investment Highlights
19 19 iBio Investment Highlights Non - Confidential 19 Proprietary Platform Contract Development & Manufacturing Organization (CDMO); $100 million state - of - the - art facility; global patent portfolio and significant know - how Majority - owned treatment candidate for fibrotic disease; additional
Slide 21: iBio Projected Milestones
iBio Projected Milestones Positive Cash Flow iBio CDMO Operation within 2018 20 Non - Confidential TImeline 2018 2019 2020 2021 New CDMO Contracts Collaborative Product Development Agreements Expand Business Agreements in Emerging Markets Initiate Phase 1 Clinical Trial of IBIO - CFB03
Slide 22: Capitalization Table
21 21 Capitalization Table Non - Confidential 21 Capitalization Table (As of 06.11.2018 ) # of Shares WAEP $ Value % of Fully Diluted Common Shares Outstanding (Directors & Officers) 154,467 1.19% Common Shares Outstanding (Other) 11,437,384 88.2% Warrants - Stock Options 1,376,333 $12.10 $16,653,63
Slide 23: Management Team
22 22 Management Team Non - Confidential 22 • Robert B. Kay – CEO and Executive Chairman – Accomplished business strategist, senior manager with M&A, JV, international licensing expertise – JD from New York University (NYU); BA from Cornell University • Robert L. Erwin – President – Founded Large Sc
Slide 24: Contact Information
23 Contact Information iBio Inc. 600 Madison Avenue, Suite 1601 New York, NY 10022 302.355.0650 23 Non - Confidential Investor Relations 302.355.9452 ir@ibioinc.com